These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10344911)

  • 21. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
    Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
    Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
    Fulton B; Spencer CM
    Drugs; 1996 Jun; 51(6):1075-92. PubMed ID: 8736622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
    Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
    Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel: a review of its use in non-small cell lung cancer.
    Comer AM; Goa KL
    Drugs Aging; 2000 Jul; 17(1):53-80. PubMed ID: 10933515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
    Schneeweiss A; Lenz F; Beldermann F; Geberth M; Goerner R; Solomayer E; Bastert G
    Zentralbl Gynakol; 2001 Sep; 123(9):520-8. PubMed ID: 11709745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
    Vu T; Ellard S; Speers CH; Taylor SC; de Lemos ML; Hu F; Kuik K; Olivotto IA
    Ann Oncol; 2008 Mar; 19(3):461-4. PubMed ID: 18006892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
    Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.